Catalog No.
PHD08201
Species reactivity
Human, Mouse
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human BRAF (Asn500-His766).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
BRAF1,RAFB1,Proto-oncogene B-Raf,BRAF,v-Raf murine sarcoma viral oncogene homolog B1,p94,Serine/threonine-protein kinase B-raf
Purification
Purified by antigen affinity column.
Accession
P15056
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment., PMID:40526090
Precision medicine approaches to CNS metastatic disease., PMID:40518193
Retrospective stratified analysis of resistance mechanisms to anti-EGFR therapy in mCRC using tumor tissue samples., PMID:40467730
First-line treatment with a combination of immunotherapy, anti-EGFR monoclonal antibodies, and chemotherapeutics for unresectable left KRAS/BRAF wild-type microsatellite-stable colorectal cancer: a case report., PMID:40460045
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study., PMID:40449497
New Standards in the Treatment of Advanced Metastatic Melanoma: Immunotherapy and BRAF-Targeted Therapies as Emerging Paradigms., PMID:40442907
Using liquid biopsies to guide treatment and monitor response in BRAF V600E positive adenocarcinoma of unknown primary., PMID:40425210
miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer., PMID:40414859
Clinical Impact of Sub-Clonal RAS/BRAF Alterations in Liquid Biopsies From Patients With Advanced or Metastatic CRC., PMID:40374470
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy., PMID:40345491
Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial., PMID:40345056
KRAS/NRAS/BRAF mutational profile and association with clinicopathological characteristics in patients with metastatic colorectal cancer., PMID:40342724
Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy., PMID:40331873
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial., PMID:40328753
The prognostic value of halp score in predicting the efficacy of nivolumab treatment in metastatic malignant melanoma patients: A real-life, retrospective, single center analysis., PMID:40324274
Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial., PMID:40279684
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial., PMID:40234093
Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras., PMID:40228175
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer., PMID:40222201
Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancer., PMID:40210835
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma., PMID:40204154
[A Case of an Older Patient with MSI-High Colorectal Cancer with Distant Lymph Node Metastasis Successfully Treated with Pembrolizumab]., PMID:40189768
BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice., PMID:40172088
Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis., PMID:40167580
Exploring the Dynamics of Immune Checkpoint Inhibitor-Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis., PMID:40145321
Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance., PMID:40141188
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma., PMID:40136348
BRAF V600E protein detection by immunohistochemistry in metastatic colorectal cancer tissue: association with tumor characteristics and KRAS mutation., PMID:40135701
Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment., PMID:40130804
An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer., PMID:40126545
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial., PMID:40107157
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals., PMID:40102447
Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations., PMID:40097366
BRAF p.V600E-Negative Langerhans Cell Histiocytosis Associated with a Periapical Cyst: A Case Presentation with Broad Review of the Differential Diagnosis and Disease Pathophysiology., PMID:40088330
Sustained Immunotherapy Response in Metastatic Brain Melanoma Through 2 Pregnancies., PMID:40083082
[New systemic treatment approaches for conjunctival melanoma]., PMID:40067450
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives., PMID:40066702
Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer., PMID:40014187
A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report., PMID:40013148
Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report., PMID:39996388
RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs., PMID:39992626
A comprehensive evaluation of a bioanalytical technique for Encorafenib and Cetuximab combination Cancer therapy by LC-MS/MS and their pharmacokinetics in plasma., PMID:39987856
Spitz Spindle Cell/Reed Nevus With SQSTM1 :: NTRK2 Fusion and Atypical Features in an Older Male Patient: A Case Report and Review of Literature., PMID:39980385
BANCR-containing extracellular vesicles enhance breast cancer resistance., PMID:39947472
Comparison of survival outcomes for patients with Lynch vs non-Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy., PMID:39932790
Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice., PMID:39932529
Immunolipid magnetic bead-based circulating tumor cell sorting: a novel approach for pathological staging of colorectal cancer., PMID:39927117
Correlation of TgAb With Clinicopathological Features and Unfavorable Efficacy of 131I Ablation in PTC., PMID:39918837
EGFR inhibition augments the therapeutic efficacy of the NAT10 inhibitor Remodelin in Colorectal cancer., PMID:39905540
For research use only. Not for human or drug use.
